Evaluating the Impact of CYP1A2 Inhibition on the Pharmacokinetics of Savolitinib: A Phase 1 Open-Label Study.
Kowser Miah, Jitendar Reddy, Pradeep Sharma et al.
✦ AI-curated · Sources linked
In 30 seconds
This Phase 1 open-label study assessed the effects of CYP1A2 inhibition by fluvoxamine on the pharmacokinetics of savolitinib in 16 healthy male volunteers. Results indicated that co-administration of fluvoxamine increased the systemic exposure of savolitinib by approximately 2-fold for maximum plasma concentration and 3-fold for area under the curve compared to savolitinib alone.
Key findings
- Savolitinib's maximum plasma concentration increased by approximately 2-fold when co-administered with fluvoxamine.
- The area under the plasma concentration-time curve for savolitinib increased by approximately 3-fold with fluvoxamine.
- Systemic exposure of M2 decreased while M3 increased when savolitinib was administered with fluvoxamine.
Why it matters
Understanding drug-drug interactions is crucial for optimizing treatment regimens, particularly in oncology, where medications like savolitinib are used. This study highlights the significant impact of CYP1A2 inhibition on savolitinib pharmacokinetics, which may influence clinical decision-making.